Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
In the latest session, Capricor Therapeutics Inc (NASDAQ: CAPR) closed at $5.04 up 4.56% from its previous closing price of $4.82. In other words, the price has increased by $4.56 from its previous closing price. On the day, 0.92 million shares were traded. CAPR stock price reached its highest trading level at $5.6463 during the session, while it also had its lowest trading level at $5.0.
Ratios:
For a deeper understanding of Capricor Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.63 and its Current Ratio is at 1.63. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.22.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on January 05, 2024, initiated with a Overweight rating and assigned the stock a target price of $8.
On October 26, 2022, Ladenburg Thalmann started tracking the stock assigning a Buy rating and target price of $15.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 12 ’23 when Musket David B bought 410 shares for $2.75 per share. The transaction valued at 1,128 led to the insider holds 31,536 shares of the business.
COLLIER EARL M JR bought 10,000 shares of CAPR for $28,300 on Oct 10 ’23. The Director now owns 26,856 shares after completing the transaction at $2.83 per share. On Oct 09 ’23, another insider, Musket David B, who serves as the Director of the company, bought 5,083 shares for $2.82 each. As a result, the insider paid 14,334 and bolstered with 31,126 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CAPR now has a Market Capitalization of 158775120 and an Enterprise Value of 121002512. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.31 while its Price-to-Book (P/B) ratio in mrq is 6.95. Its current Enterprise Value per Revenue stands at 4.806 whereas that against EBITDA is -5.259.
Stock Price History:
The Beta on a monthly basis for CAPR is 4.09, which has changed by 0.29896903 over the last 52 weeks, in comparison to a change of 0.22640884 over the same period for the S&P500. Over the past 52 weeks, CAPR has reached a high of $8.22, while it has fallen to a 52-week low of $2.68. The 50-Day Moving Average of the stock is -8.49%, while the 200-Day Moving Average is calculated to be 7.29%.
Shares Statistics:
For the past three months, CAPR has traded an average of 293.57K shares per day and 468760 over the past ten days. A total of 31.15M shares are outstanding, with a floating share count of 28.91M. Insiders hold about 8.22% of the company’s shares, while institutions hold 12.81% stake in the company. Shares short for CAPR as of 1711584000 were 3501729 with a Short Ratio of 11.93, compared to 1709164800 on 2699771. Therefore, it implies a Short% of Shares Outstanding of 3501729 and a Short% of Float of 13.4.
Earnings Estimates
Currently, 3.0 analysts are dedicated to thoroughly evaluating and rating the performance of Capricor Therapeutics Inc (CAPR) in the stock market.On average, analysts expect EPS of -$0.11 for the current quarter, with a high estimate of $0.03 and a low estimate of -$0.26, while EPS last year was -$0.31. The consensus estimate for the next quarter is -$0.29, with high estimates of -$0.26 and low estimates of -$0.32.
Analysts are recommending an EPS of between -$0.75 and -$1.36 for the fiscal current year, implying an average EPS of -$0.96. EPS for the following year is $0.1, with 4.0 analysts recommending between $1.44 and -$1.21.
Revenue Estimates
A total of 3 analysts believe the company’s revenue will be $9.7M this quarter.It ranges from a high estimate of $14.1M to a low estimate of $5M. As of the current estimate, Capricor Therapeutics Inc’s year-ago sales were $2.99MFor the next quarter, 3 analysts are estimating revenue of $4.41M. There is a high estimate of $5M for the next quarter, whereas the lowest estimate is $3.92M.
A total of 3 analysts have provided revenue estimates for CAPR’s current fiscal year. The highest revenue estimate was $30M, while the lowest revenue estimate was $27.2M, resulting in an average revenue estimate of $28.53M. In the same quarter a year ago, actual revenue was $25.18MBased on 3 analysts’ estimates, the company’s revenue will be $119.36M in the next fiscal year. The high estimate is $185M and the low estimate is $22.5M.
